Bellerophon Therapeutics (BLPH) Getting Somewhat Favorable Media Coverage, Accern Reports

Media coverage about Bellerophon Therapeutics (NASDAQ:BLPH) has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.3094819430512 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the headlines that may have effected Accern’s analysis:

NASDAQ BLPH traded down $0.05 on Friday, reaching $2.87. The company had a trading volume of 287,496 shares, compared to its average volume of 519,249. The firm has a market cap of $167.81 million, a PE ratio of -3.19 and a beta of -0.42. Bellerophon Therapeutics has a 1-year low of $1.00 and a 1-year high of $3.30.

A number of equities analysts recently weighed in on the stock. ValuEngine raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 8th. HC Wainwright reaffirmed a “buy” rating on shares of Bellerophon Therapeutics in a research note on Friday, May 11th. Finally, Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Thursday, March 22nd.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Insider Buying and Selling by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply